Welcome Guest, Give the Gift of Health to Your Loved Ones
MPT: Morning Break: PCSK9 Drug Dropped Pfizer said it was axing its investigational PCSK9 inhibitor bococizumab, citing trial results showing more adverse effects and less long-term efficacy than other drugs in the class.
Pfizer Press Release: Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor With the completion of six bococizumab lipid-lowering studies, Pfizer has observed an emerging clinical profile that includes an unanticipated attenuation of low-density lipoprotein cholesterol (LDL-C) lowering over time, as well as a higher level of immunogenicity and higher rate of injection-site reactions with bococizumab than shown with the other agents in this class. The goal of treating elevated cholesterol is to reduce the occurrence of cardiovascular events such as heart attacks and stroke, which requires long-term effective and durable cholesterol-lowering. …
The release didn't speak of events (or all-cause mortality), but we may eventually learn of those results, because: …Pfizer has committed to ensuring that the data will be made available to study leaders for independent analysis and prompt public presentation. …
The good news here, I suppose, is that now we won't have to learn how to pronounce "Bococizumab", although I imagine they were working on a trendy retail branding for it, perhaps "Lipidown".
___________ Bob Niland [disclosures] [topics]